𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Incidence of high-risk acute coronary syndromes and eligibility for glycoprotein IIb/IIIa inhibitors among patients admitted for possible myocardial ischemia

✍ Scribed by Michael C. Kontos; Joseph P. Ornato; Kristin L. Schmidt; James L. Tatum; Robert L. Jesse

Book ID
117842663
Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
84 KB
Volume
143
Category
Article
ISSN
1097-6744

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Randomized evaluation of the efficacy of
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial
✍ David H. Fitchett; Anatoly Langer; Paul W. Armstrong; Mary Tan; Aurora Mendelsoh πŸ“‚ Article πŸ“… 2006 πŸ› Elsevier Science 🌐 English βš– 142 KB
Efficacy and safety of enoxaparin compar
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
✍ Harvey D. White; Neal S. Kleiman; Kenneth W. Mahaffey; Yuliya Lokhnygina; Karen πŸ“‚ Article πŸ“… 2006 πŸ› Elsevier Science 🌐 English βš– 333 KB